Richard Saynor

Richard Saynor, CEO of Sandoz, dives deep into the ramifications of President Trump's proposed tariffs on imported pharmaceuticals. He outlines the minimal incentives for U.S. manufacturing and how these tariffs threaten the affordability and availability of generic drugs. Saynor also compares brand-name and generic companies, discussing the ethical dilemmas of rising costs for patients. He emphasizes the need for structural reforms in the generics industry as a critical step towards improving access to affordable medications in the shifting landscape of U.S. pharma.

Richard Saynor, CEO of Sandoz, shares insights on how U.S. tariffs are reshaping the pharmaceutical landscape, particularly in generic drug production. He discusses manufacturing decisions influenced by trade policies and the challenges faced in a competitive market. Frances Coppola, an independent economist, analyzes the recent interest rate cuts and their implications for UK households. The podcast also explores the booming trend of staycations and the evolving dynamics in both travel and manufacturing sectors, highlighting the broader economic landscape.